Current FDA Approval Status for Mounjaro
Mounjaro (tirzepatide) received initial FDA approval in 2022 for type 2 diabetes under the brand name Mounjaro. The same drug is now approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity when used with a reduced-calorie diet and increased physical activity. The approval was based on the SURMOUNT clinical trial program, which demonstrated significant and sustained reductions in body weight compared to placebo. Eli Lilly, the manufacturer, filed the supplemental new drug application for the weight loss indication after the trials met their primary endpoints. For the latest regulatory filings, you can check the official FDA page for Mounjaro on the FDA website.
The FDA label for Mounjaro specifies a BMI threshold of 30 kg/m² for obesity or 27 kg/m² for overweight with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. The dosing regimen starts at 2.5 mg once weekly for four weeks, then increases to 5 mg once weekly, with further titration steps up to a maintenance dose of 15 mg once weekly. Real-world adoption has been rapid, with Mounjaro becoming one of the most prescribed GLP-1 receptor agonist-based weight loss therapies in the U.S. shortly after the new indication was approved. For more detailed prescribing information, see the official Mounjaro prescribing information on Eli Lilly's website.
Eligibility Criteria and Clinical Evidence
Eligibility for Mounjaro for weight loss requires a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity. Patients must also commit to ongoing lifestyle interventions, including a reduced-calorie diet and regular physical activity, as part of the treatment plan. The SURMOUNT-1 trial, a pivotal phase 3 study, showed an average weight loss of approximately 22.5% of initial body weight at 72 weeks for the highest dose group compared to 2.4% with placebo. The trial enrolled adults without diabetes, which distinguishes the weight loss indication from the diabetes approval. For a summary of the clinical trial data, see the peer-reviewed publication on the SURMOUNT-1 trial results.
Common side effects reported in the trials include nausea, diarrhea, decreased appetite, constipation, vomiting, and injection site reactions. The FDA label includes warnings about the risk of acute pancreatitis, gallbladder problems, and low blood sugar when used with insulin or sulfonylureas. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Because of these risks, prescribers are required to conduct a thorough medical history before initiating treatment. For additional safety details, refer to the FDA's drug safety communication on tirzepatide.
Insurance Coverage and Real-World Access
Insurance coverage for Mounjaro for weight loss varies widely among commercial plans, Medicare, and Medicaid. Many private insurers now cover Mounjaro for the FDA-approved weight management indication when specific medical necessity criteria are met, such as documented obesity or overweight with a comorbidity. However, prior authorization is typically required, and some plans impose step therapy requirements or limit coverage to certain dosage strengths. Medicare Part D coverage for Mounjaro for weight loss remains limited, as Medicare generally does not cover drugs for weight loss unless they are FDA-approved for a non-weight-related indication, though coverage policies are evolving. For the latest coverage policies, see the Centers for Medicare & Medicaid Services guidance on obesity treatments.
Real-world access has been affected by supply constraints and high list prices, with Mounjaro's cash price often exceeding 1,00